The gut microbiota and irritable bowel syndrome: friend or foe?
The gut microbiota and irritable bowel syndrome: friend or foe?
复制标题
肠道菌群和肠易激综合症：朋友还是敌人？
DOI：
10.1155/2012/151085
复制
发表时间：
2012
影响因子：
2
通讯作者：
Quigley EM
中科院分区：
文献类型：
--
作者：
Ghoshal UC;Shukla R;Ghoshal U;Gwee KA;Ng SC;Quigley EM
肠易激综合征（IBS）的病理生理学的理解进展，曾经被认为是一种纯粹的心身疾病，已经取得了相当大的进展，低度炎症和肠道微生物群的变化现在具有潜在的重要性。人类肠道拥有巨大的微生物生态系统，其具有多种功能，如食物消化，药物代谢，有毒化合物解毒，必需维生素的产生，防止病原菌附着于肠道壁，以及维持胃肠道内的稳态。IBS患者的一个子集可能在小肠中细菌数量增加（小肠细菌过度生长）。肠道微生物群的质的变化也与IBS有关。使用益生菌和抗生素靶向肠道微生物群已成为治疗这种迄今为止神秘的功能性肠病的潜在有效方法。本文就IBS患者健康时肠道菌群、菌群数量和质量变化以及针对菌群的治疗措施进行综述。
Progress in the understanding of the pathophysiology of irritable bowel syndrome (IBS), once thought to be a purely psychosomatic disease, has advanced considerably and low-grade inflammation and changes in the gut microbiota now feature as potentially important. The human gut harbours a huge microbial ecosystem, which is equipped to perform a variety of functions such as digestion of food, metabolism of drugs, detoxification of toxic compounds, production of essential vitamins, prevention of attachment of pathogenic bacteria to the gut wall, and maintenance of homeostasis in the gastrointestinal tract. A subset of patients with IBS may have a quantitative increase in bacteria in the small bowel (small intestinal bacterial overgrowth). Qualitative changes in gut microbiota have also been associated with IBS. Targeting the gut microbiota using probiotics and antibiotics has emerged as a potentially effective approach to the treatment of this, hitherto enigmatic, functional bowel disorder. The gut microbiota in health, quantitative and qualitative microbiota changes, and therapeutic manipulations targeting the microbiota in patients with IBS are reviewed in this paper.